The tumour microenvironment (TME) has demonstrated importance to lung cancer biology. In particular, the presence of specific bacterial species in the gut has been associated with a response to checkpoint blockade in lung cancers [2]. It is possible that, in addition to their immune modulatory effect, commensal microbes may also secrete modulators or generate metabolites to potentiate tumour cells sensitivity to apoptosis induction and, thereby, rendering cancer patient response to ICI immunotherapy [3]. Nowadays, it has been shown that bacterial communities are different in the tumour compared with the surrounding non-malignant cells. One of the reasons for the poor survival in lung cancer is late disease detection. The presence of certain bacteria in the airways could serve as an indicator for lung cancer development. At present, it is unclear at what stage during cancer development this bacterial shift occurs.
To assess the role of the microbiota in cancer development PhD candidate Erin Marshall (University of British Columbia, Canada) and her team analysed the airway microbiota after bronchoscopy in a cohort of high-risk patients: 3 participants were shown to have current cancer, 40 had no cancer, and 5 developed cancer in a follow-up period of 9.2 years (i.e. the incident cancer group).
An analysis of the diversity of the microbiome revealed a cluster of cancer and incident-cancer patient samples compared with the patients with no cancer. This suggests that the microbiome of patients who will develop cancer in a time frame of 3 months to 4.5 years exhibits similarity to the microbiome of patients who already have clinically detectable cancer. In a second cohort, the researchers found a relative abundance of Bacilli/Lactobacillales in participants who went on to develop cancer during the follow-up period. In addition, the Paenibacillaceae family increased in patients with incident cancer and cancer. This facultative anaerobe genus is a known opportunistic infector of humans. Its abundance is associated with a wide variety of diseases including cancers such as gastric cancer. In addition, it is commonly observed in immunocompromised patients, for example, in the elderly and in those with weak immune systems. The analysis further showed 5 pathways significantly associated with incident-cancer patient airways: the deregulation of RNA transport, taurine and hypotaurine metabolism, linoleic acid metabolism, and the formation of biofilm.
The authors concluded that bacteria in non-malignant airway cells may be associated with cancer initiation. Distinct microbiome profiles in the airways can identify patients that develop incident cancers. “While preliminary, this work indicates the possible future role of microbiome in lung cancer prediction and screening,” concluded Ms Marshall.
- Marshall EA, et al. Distinct Lung Microbiome Preceding Clinical Diagnosis of Lung Cancer. A4249. ATS Virtual Congress 2020, 5-10 August.
- Elkrief A, et al. Gut Microbes 2019; 10: 424-428.
- Liu K, Lu C. Transl Cancer Res 2018;7(Suppl 5): S 608-10.
Posted on
Previous Article
« LEAD study shows multiple phenotypes in many chronic cough patients Next Article
Biomarkers: a novel tool to improve lung nodule classification »
« LEAD study shows multiple phenotypes in many chronic cough patients Next Article
Biomarkers: a novel tool to improve lung nodule classification »
Table of Contents: ERS 2020
Featured articles
COVID-19 and the Lung
COVID-19 infections: Bronchoscopy provides additional diagnostic certainty
COVID-19 vaccines: An ongoing race
COVID-19: What is the risk of reinfection?
COVID-19 App: The Dutch experience
Secondary pulmonary fibrosis: a possible long-term effect of severe COVID-19
COVID-19 survivors benefit from structured follow-up
Early pulmonary rehabilitation post-COVID-19 aids recovery
Asthma – What's New
Mild asthma: A fundamental change in management
Dupilumab shows long-term efficacy in asthma patients
Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity
First-in-class tyrosine kinase inhibitor shows promise in severe asthma
Predicting individual effectiveness of biologics in severe asthma
IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps
Treatment according to genotype: The future of asthma therapy?
COPD – The Beat Goes On
The role of chronic symptoms as early biomarkers of COPD development
Urgent call for studies in COPD patients aged 40-60 years
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients
Exacerbation history is a reliable predictor of future exacerbations
Singing training effective as physical rehabilitation in COPD
Current prediction tools underestimate exacerbation risk of severe COPD patients
Exercise and Sleep: From Impaired Function to New Therapeutic Strategies
CPAP withdrawal has negative consequences for sleep apnoea patients
Physical activity improves AHI in sleep apnoea patients
The Tobacco Epidemic: From Vaping to Cannabis
Poly-use of nicotine products and cannabis: a deadly combination
E-cigarettes: A source of chronic lung inflammation
Social smoking: Do not underestimate the risks
Chronic Cough – State of the Art
LEAD study shows multiple phenotypes in many chronic cough patients
First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment
Lung Cancer Detection
Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis
Distinct changes in lung microbiome precede clinical diagnosis of lung cancer
Best of Posters
Smartphone-based cough detection helpful in predicting asthma deterioration
Reduced lung function associated with cognitive decline in the elderly
Longer hospital stay and fewer transplants for frail ILD patients
Related Articles
July 18, 2022
New guidelines for IPF and PPF
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com